# Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia

> **NCT05987696** · PHASE1 · COMPLETED · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 2 (actual)

## Conditions studied

- AML, Adult
- Minimal Residual Disease

## Interventions

- **DRUG:** CD33/CLL1 dual CAR-NK cell
- **DRUG:** Cyclophosphamid
- **DRUG:** Fludarabine
- **DRUG:** Cytarabine
- **DRUG:** CD33 CAR-NK cell
- **DRUG:** super NK cell

## Key facts

- **NCT ID:** NCT05987696
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-31
- **Primary completion:** 2025-01-17
- **Final completion:** 2025-01-17
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2026-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05987696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05987696, "Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05987696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*